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Eﬀects of the Antiandrogen Flutamide on the Expression
of Protein Kinase C Isoenzymes in LNCaP and PC3
Human Prostate Cancer Cells
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Manuel Sa´nchez-Chapado,2 and Juan C. Prieto1,3
Flutamide is a nonsteroidal antiandrogen that is frequently used for total androgen
blockage in the treatment of advanced prostate cancer. We investigated the eﬀect of this
antiandrogen on the expression of protein kinase C (PKC) isoenzymes (a, b1, e, f) that are
involved in cell growth, apoptosis and neoplastic transformation. Androgen-dependent
(LNCaP) and independent (PC3) human prostate cancer cells were cultured in a medium
that contained fetal bovine serum (FBS) or charcoal-stripped serum (CSS) and treated with
10 lM ﬂutamide. The expression of PKC isoenzymes and the androgen receptor (AR) were
analyzed by Western blot and RT-PCR, respectively. Serum steroids diﬀerentially regulate
the expression of PKC isoenzymes in LNCaP and PC3 cells. Flutamide up-regulated the
expression of a, b1 and f, but not e, PKC isoenzymes in CSS-LNCaP cells. These results
were not homogeneously reproduced in the presence of androgens. We observed an opposite
eﬀect of ﬂutamide, compared to CSS, on PKCb1 isoform expression in CSS-LNCaP sug-
gesting that this antiandrogen exerts an agonistic eﬀect. In PC3 cells ﬂutamide potentiated
the expression of the four PKC isoenzymes in almost all conditions tested (FBS- and CSS-
cultured cells). Such eﬀect of ﬂutamide in PC3 cells is independent of AR since no expression
of AR was detected. These results provide new evidence on antagonistic/agonistic responses
of prostate cancer cells to antiandrogen drugs that are widely used in therapy and show that
ﬂutamide can elicit responses in prostate cancer cells that do not express AR.
KEY WORDS: Protein kinase C isoenzymes, antiandrogen, ﬂutamide, androgen receptor,
prostate cancer.
INTRODUCTION
Protein kinase C (PKC) isoenzymes regulate important cellular processes such as
proliferation, diﬀerentiation, apoptosis and neoplastic transformation [1, 2]. The
isoenzymes have deﬁned cellular functions and are arranged into three groups:
conventional PKCs (a, b1, b2, c), which are Ca2+-dependent and activated by
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diacylglycerol (DAG) or phorbol esters and phosphatidylserine (PS); novel PKCs (d,
e, g, h), which are Ca2+-independent but are activated by DAG and PS; and atypical
PKCs (f, z, k), which are Ca2+- and DAG-independent but are PS sensitive [3, 4].
Prostate cancer is a leading cause of cancer death among men in Western
countries. There is an emerging understanding of the role played by PKC isoen-
zymes in the regulation of prostate cancer cell growth and programmed death
which may provide novel therapeutic targets during the progression of the disease
[5–8]. Advanced prostate cancer is commonly treated by surgical or chemical cas-
tration in combination with antiandrogens. This results in androgen ablation that
suppresses cell proliferation and activates apoptosis in androgen-dependent cells [9].
The primary role of androgens on the proliferation and functionality of prostate
cells [10] provides the rationale for this therapy. Unfortunately, the treatment is
only palliative since prostate cancer progresses despite antiandrogen administration
because of the emergence of androgen-independent cells [11]. This is a gradual
transition accompanied by a complex array of molecular events including mutation
of androgen receptors (AR), gene ampliﬁcation, co-regulators and signal trans-
duction cross-talk [12, 13]. Interestingly, AR mutations may result in a shift in the
behavior of AR ligands, i.e., from antagonist to agonist properties, as has been
suggested for ﬂutamide. In this regard, treatment with this nonsteroidal antian-
drogen elicited paradoxical agonistic responses in both human prostate cancer
tissue with AR gene mutations [14, 15] and in androgen-dependent LNCaP cells
[16]. The AR mutation in LNCaP consists of a single nucleotide substitution,
resulting in one amino acid change in the ligand-binding domain of the receptor
(T877A) [17]. As a consequence of this mutation, the AR is activated in response to
unusual ligands such as estrogens and progestagens, as well as antiandrogens
[17, 18]. Flutamide has also been reported to behave as a weak partial agonist of
the wild type AR [15]. We have previously shown that treatment of rats with
ﬂutamide blocks adenylate cyclase activation through G-protein coupled receptors
in prostate cell membranes [19], a pattern that is also evoked by PKC activation in
rat prostate cells [20]. Moreover, we have recently observed that ﬂutamide up-
regulates the expression of diﬀerent PKC isoenzymes in both normal and castrated
rat prostates [21]. In the present report, we address the study of the regulation of
the expression of four (a, b1, e, f) PKC isoforms in prostate cancer cells by
ﬂutamide and by androgen availability. To this aim, we used androgen-dependent
(LNCaP) and androgen-insensitive (PC3) human prostate cancer cells that were
cultured with ﬂutamide in a medium containing either fetal bovine serum (FBS) or
charcoal-stripped serum (CSS).
MATERIALS AND METHODS
Cells and Reagents
The human prostate cancer cell lines LNCaP and PC3 were purchased from the
American Type Culture Collection (Rockville, MD, USA). Rabbit polyclonal
antibodies against PKC isoenzymes (anti-a: sc-208; anti-bI: sc-209; anti-f: sc-216
and anti-e: sc-214) were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). The anti-rabbit IgG horseradish peroxidase conjugate was from
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Calbiochem-Novabiochem (San Diego, CA, USA). The peroxidase system Super-
signal kit for Western blotting was from Pierce (Rockford, IL, USA). Media, sera,
and penicillin/streptomycin for cell culture were from Gibco (Barcelona, Spain);
oligonucleotides for PCR and chemiluminescence ﬁlm were from Amersham Phar-
macia Biotech (San Cugat, Spain). Molecular-weight markers and protein electro-
phoresis reagents were from Bio-Rad (Hercules, CA, USA). The Ultraspec kit for
RNA extraction was from Biotecx (Houston, TX, USA) and the Ecotaq polymerase
from Ecogen (Barcelona, Spain). Flutamide and other reagents were from Sigma
(Alcobendas, Spain).
Cell Culture and Cellular Fractionation
LNCaP and PC3 cells were maintained in RPMI-1640 supplemented with 10%
FBS, 100 units penicillin and 0.1 mg/ml streptomycin and passaged weekly. Some
experiments in both cell lines involved keeping the cells in 10% CSS to remove
steroids. CSS was obtained by treatment of FBS with charcoal/Dextran T70 (10:1,
w/w) followed by low-speed centrifugation [22]. Before antiandrogen treatment, cells
were grown for 3 days in medium supplemented with 10% FBS or CSS. Thereafter,
the cells were treated for 24 h with 10 lM ﬂutamide, washed twice with cold
phosphate buﬀered saline (PBS) and scraped in 1 ml cold homogenization buﬀer
consisting of 20 mM Tris-HCl (pH 7.5) supplemented with 5 mM EDTA, 5 mM
EGTA, 12.8 mM b-mercaptoethanol, 10 mM benzamidine, 0.3 mM phen-
ylmethylsulfonilﬂuoride (PMSF), 25 lg/ml leupeptine and 0.01% serum trypsin
inhibitor (STI). The homogenate was kept at )80C for 30 min to lyse the cells.
Protein concentration was determined [23], using bovine serum albumin as a stan-
dard.
Western Blot Analysis of PKC Isoenzymes
Sample aliquots with equivalent amounts of protein (15 lg) were boiled, frac-
tionated in 8% SDS-PAGE, and transferred onto a 0.45 lm nitrocellulose mem-
brane. After transfer, the membranes were blocked for 2 h at room temperature with
a solution of 5% (w/v) fat-free milk in 20 mM Tris (pH 7.4)/137 mM NaCl, con-
taining 0.1% (v/v) Tween-20 (TBST). Incubation with the primary antibodies (anti-
PKC a, b1, e, f) was performed for 90 min at 4C, followed by three washes with
TBST containing 5% fat-free milk and incubation with the secondary antibody for
1 h at 4C. Immunoreactive bands were detected by enhanced chemiluminescence
using the Supersignal kit (Pierce) according to the manufacturer’s directions. Bands
were quantiﬁed by densitometric scanning using Scion Image software (Scion Cor-
poration, MD, USA). Controls for the immunochemical studies were carried out by
replacing the primary antibodies by TBST and incubating with the secondary anti-
body according to the above protocol.
RNA Isolation and AR RT-PCR
Total cell RNA was isolated using the Ultraspec kit. Two lg of RNA was
reverse transcribed by the Moloney murine leukemia virus reverse transcriptase
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(Gibco) at 37C for 60 min in a 20 ll mixture with hexamer random primers
(Gibco). PCR was performed with human speciﬁc AR primers. The nucleotide bases
were 5¢-TCACACATTGAAGGCTATGA-3¢ for the upstream primer, and
5¢-GTGGAAATAGATGGGCTTGA-3¢ for the downstream primer [24]. A 2.5 ll
volume of the reverse-transcribed mixture was subjected to PCR in a 25 ll mixture
consisting of 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 3 mM MgCl2, 1 mM of each
dNTP, 0.5 units of EcoTaq polymerase, and 0.5 pmol of the primers. Thirty-ﬁve
cycles of reaction at 94, 55 and 72C for 30, 60 and 60 s, respectively, were carried
out in a PTC-100 Programmable Thermal Controller (MJ Research, Inc., Waltham,
MA, USA). Ampliﬁed cDNA was subjected to electrophoresis in a 1.2% agarose gel
containing 100 ng/ml ethidium bromide. After electrophoresis, gels were viewed and
photographed under UV light illumination.
Statistical Analysis
The results are expressed either as the mean ± SEM or as representative
experiments. When appropriate, statistical signiﬁcance was assessed by ANOVA and
the Student’s t test. The level of signiﬁcance was regarded at p < 0.05.
RESULTS
Western blot analysis with speciﬁc antisera allowed us to detect the four PKC
isoenzymes studied (a, b1, e, f) in both androgen-dependent (LNCaP) and androgen-
insensitive (PC3) human prostate cancer cells. This was true either in the presence or
absence of androgens (i.e., culturing the cells with FBS or CSS, respectively) (Fig. 1).
The observation of a second, faint band in some cases could be associated to dif-
ferent states of protein phosphorylation. It should be noted that PKC activity is
achieved by both subcellular localization and phosphorylation, and Western-blots
performed in the present study were carried out in whole cell lysates. There were
diﬀerent patterns of band intensity in the Western-blots of the PKC isoenzymes
depending on the androgen dependence of the cell line: band intensity in control
conditions (FBS) was similar in both cell lines for the b1 and f isoenzymes whereas
the a and e isoenzymes exhibited higher density values in PC3 cells as compared with
LNCaP cells. We analyzed the eﬀect of CSS (compared to FBS) on the level of
expression of PKC isoenzymes in both cell lines. Densitometric quantitation of
Western blot analysis of a, b1, e and f PKC isoforms in LNCaP and PC3 cells is
shown in Fig. 1. In CSS-cultured LNCaP cells, we observed diﬀerential regulation of
the expression of PKC isoenzymes: increased expression of PKCa and PKCf, no
signiﬁcant change in PKCe expression, and decreased expression of PKCb1. On the
other hand, in CSS-cultured PC3 cells we observed a very signiﬁcant up-regulation of
PKCe expression and similar increases in the expression of PKCa and f, whereas no
signiﬁcant changes for PKCb1 expression were found.
We have previously observed that ﬂutamide increases the expression of ventral
prostate PKC isoenzymes (a, b, f and e) from both control and castrated rats [21].
In this study we analyzed the eﬀect of ﬂutamide on the level of expression of these
four PKC isoenzymes in LNCaP and PC3 human prostate cancer cells. Densito-
metric quantitation of Western blot analysis of a, b1, e and f PKC isoforms in
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LNCaP and PC3 cells is shown in Figs. 2 and 3. In order to analyze the eﬀect of
ﬂutamide, we normalized the data by representing them as a percentage of their
respective controls (FBS or CSS). In the absence of androgens (i.e., with CSS) it
can be seen that ﬂutamide consistently increased, in a statistically signiﬁcant
manner, the expression of the four PKC isoenzymes in both cell lines (with the
exception of PKCe in LNCaP cells and PKCf in PC3 cells). However, some het-
erogeneity was observed when androgens were present (i.e. with FBS): in LNCaP
cells, ﬂutamide did not modify PKCa, f or e expression and inhibited PKCb1
expression; in PC3 cells, the antiandrogen increased the expression of three PKC
isoenzymes (b1, b and e) and did not exert any eﬀect on PKCa expression. These
results are summarized in Table 1, where densitometric data are expressed as a
percentage of control 1 (FBS).
Surprisingly, ﬂutamide up-regulates the expression of the four PKC isoenzymes
studied in PC3 cells (Fig. 3). Since this cell line does not express the AR, which is the
Fig. 1. Regulation of the expression of PKC isoenzymes in LNCaP
and PC3 human prostate cancer cells by serum steroid availability.
Cells were grown for 4 days in medium supplemented with 10%
FBS or CSS. Whole cell lysates were separated by SDS-PAGE and
immunoblotting was performed with PKC isoenzyme-speciﬁc anti-
bodies (a, b1, e, f) as indicated (see Methods). The intensities of the
bands were quantiﬁed by densitometry scanning and normalized by
representing them as a percentage of the control (FBS). The bars
represent means ± SEM of four experiments. *p < 0.05,
**p < 0.01 compared to control.
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known target protein for ﬂutamide binding, we examined the possibility that this
antiandrogen and/or the culture conditions could induce AR expression. Thus, we
carried out RT-PCR analysis of AR from total RNA obtained from PC3 cells
cultured in the same conditions used for PKC western blot analyses. As shown in
Fig. 4, no PCR products were detected in any of the conditions tested (with FBS or
CSS) in PC3 cells whereas, as expected, LNCaP cells were positive for AR expres-
sion. This observation leads to the conclusion that ﬂutamide induces the expression
of PKC isoforms in PC3 cells by an AR-independent mechanism.
Fig. 2. Regulation of the expression of PKC isoenzymes in LNCaP human prostate cancer cells
by androgen availability. Cells were grown for 3 days in medium supplemented with 10% FBS or
CSS, followed by an additional period of 24 hr in the absence (C1 for FBS, and C2 for CSS) and
presence (Ft) of 10 lM ﬂutamide. Whole cell lysates were separated by SDS-PAGE and immu-
noblotting was performed with PKC isoenzyme-speciﬁc antibodies (a, b1, e, f) as indicated.
Immunoreactive bands were detected by chemiluminescence (see Methods). The intensities of the
bands were quantiﬁed by densitometric scanning and normalized by representing them as a
percentage of their respective controls (C1, C2). The bars represent means ± SEM of four
experiments. *p < 0.05, **p < 0.01.
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Table 1. Eﬀect of Serum Steroids Availability and Flutamide (Ft) on the Expression of PKC Isoenzymes
in LNCaP and PC3 Human Prostate Cancer Cells
LNCaP (PKC) PC3 (PKC)
a b1 n e a b1 n e
FBS 100 100 100 100 100 100 100 100
FBSþFt 88 14 58 13* 129 13** 90 22 105 3 163 15* 132 6* 202 33**
CSS 141 2** 31 1*** 130 12** 96 29 119 4* 119 19 139 4*** 196 46**
CSSþFt 175 5*** 60 3*** 150 9*** 109 37 141 9*** 147 6*** 133 8* 242 5***
Results represent the intensity of the immunoreactive band obtained for each PKC isoenzyme. Data are
expressed as a percentage of the intensity value from the control C1 (FBS). Data represent the
mean SEM of four experiments. *p<0.01, **p<0.05, ***p<0.001.
Fig. 3. Regulation of the expression of PKC isoenzymes in PC3 human prostate cancer cells by
ﬂutamide. See legend for Fig. 2. The bars represent means ± SEM of four experiments. *p < 0.05,
**p < 0.01.
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DISCUSSION
In the present report, we have analyzed the dependence of the expression of
some selected PKC isoenzymes (a, b1, e, f) on the availability and/or action of
androgens by using androgen-dependent (LNCaP) or independent (PC3) human
prostate cancer cells and the antiandrogen ﬂutamide. The eﬀect of ﬂutamide on
the expression of these PKC isoforms, at least in PC3 cells, was independent of
AR.
By means of immunochemistry, we detected the four PKC isoenzymes studied in
both LNCaP and PC3 cells. The diﬀerential patterns observed suggest distinct roles
for these PKC isoenzymes in the mediation of androgen-related human prostate
cancer cell growth. Our observation of the presence of the classical PKCa and
PKCb1, the novel PKCe and the atypical PKCf in both cell lines agrees with pre-
vious results in DU145 androgen-insensitive human prostate cancer cells [5] and
human prostate adenocarcinoma tissue [7]. The a, e and f but not b1 isoforms have
been previously found in LNCaP cells [25]. Diﬀerences related to cell batch or to the
antibody used may underpin our ability to detect PKCb1 expression in LNCaP cells.
Moreover, we have recently observed the same pattern of expression of PKCb1 in rat
prostate [21], which has been shown to express PKCb1 mRNA [26].
PKC plays a fundamental role in the regulation of cell proliferation, diﬀeren-
tiation and survival. However, information on the speciﬁc role of individual PKC
isoenzymes is, to date, limited. Therefore, to establish in a particular cell type agents
and situations that regulate PKC expression and/or activity allows association of
PKC isoforms with speciﬁc cellular functions. PKC activation by phorbol esters
induces apoptosis in androgen-sensitive LNCaP cells by activating mainly PKCa and
PKCd but not in androgen-independent DU145 cells [8, 25]. This latter ﬁnding has
been ascribed to a defective apoptotic pathway resulting in growth and survival of
cells dependent on the constitutively active PKCa [6, 27]. Moreover, inhibition of
Fig. 4. RT-PCR analysis of the expression of AR mRNA expression in human
prostate cancer cells. RT-PCR was performed with total RNA from PC3 cells
that had been grown for 3 days in 10% FBS or CSS followed by 24 hr in the
absence or presence of 10 lM ﬂutamide as indicated in the corresponding lanes.
LNCaP cells were included in the study as AR expression positive control. As
negative control, PCR was performed without DNA. A DNA standard lane is
shown at the left of the gel, with bands labeled in base pairs. The experiment is
representative of three performed.
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PKC activity appears to be associated with growth inhibition in PC3 cells, in part
due to inactivation of PKCa [28], implying that cellular PKC activity contributes to
their faster growth rates. The observation of a similar expression of the atypical
PKCf in the two cell lines studied may be related to a previous ﬁnding by Powell
et al., who did not observe any eﬀect on tumorigenicity when an aggressive cell
subline of the Dunning 3327 rat prostate carcinoma was transfected to stably
overexpress this PKC isoform [29]. By contrast, PKCn is considered to be an on-
coprotein since its overexpression confers an oncogenic phenotype to rat ﬁbroblasts
[30]. In this regard, increased PKCn expression and attenuation of PKCb1 expres-
sion have been associated with progressive neoplasia in the diagnosis of prostate
cancer [7], in keeping with present results in PC3 cells that represent the advanced,
androgen-insensitive stage of human prostate cancer.
The eﬀect of androgens on rat prostate PKC isoenzymes has previously been
reported by Goueli [31]. He observed that castration diminished PKC activity and
that this eﬀect is reversed by androgen administration to castrated animals [31]. The
present study extends these observations to human prostate cancer cells showing
diﬀerential regulation of PKC isoforms by both androgen and AR availability. In
LNCaP cells, cultured in CSS, we observed a diﬀerential regulation of the expression
of PCK isoforms, since PKCa and PKCn were up-regulated, whereas no change was
observed PKCe. In addition, PKCb1 levels were signiﬁcantly diminished compared
to FBS conditions. This pattern of expression of PKC isoforms was slightly diﬀerent
in PC3 cells cultured in the same conditions as LNCaP cells. In PC3 cells, we
observed up-regulation of PKCe (in addition to PKCa and PKCn) and no eﬀect on
PKCb1 expression. Taken together, these results suggest: (1) that androgens and
other steroids present in serum down-regulate the expression of PKCa and PKCn
isoenzymes since these PKC isoforms exhibit a similar regulation pattern in both
LNCaP and PC3 cells; (2) that androgens up-regulate PKCb1 expression, as evi-
denced by the down-regulation observed in CSS-LNCaP cells and the absence of any
eﬀect in CSS-PC3 cells; (3) that androgens do not regulate the expression of PKCe,
since no eﬀect was observed in LNCaP cells and the up-regulation observed in PC3
cells was independent on AR.
Flutamide potentiated the expression of the four PKC isoenzymes studied in
both LNCaP and PC3 cells incubated in the absence of androgens (with the
exception of PKCe in LNCaP and PKCf in PC3 cells) whereas the results were more
heterogeneous in the presence of androgens. The nonsteroidal antiandrogen ﬂuta-
mide competes with dihydrotestosterone for binding to the AR. Therefore, it is
widely used in combination with androgen suppressive procedures and even as
monotherapy in advanced prostate cancer [9]. This drug exerts an inhibitory eﬀect on
prostate cell proliferation by blocking androgen action, as well as on bone formation
and spermatogenesis [32–34]. Interestingly, ﬂutamide has been reported to behave as
an AR agonist in human prostate cancer tissue with an AR gene mutation and in
human LNCaP cells [14–16, 18]. The agonist-like response was observed at the level
of prostate speciﬁc antigen (PSA) expression or cell growth and has important
implications for the treatment of prostate cancer. The present results extend these
observations by implicating the expression of PKC isoenzymes that modulate the
mechanisms of cell proliferation, apoptosis and neoplastic transformation [1, 2].
Whereas PC3 cells are androgen-insensitive and have lost AR expression, LNCaP
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cells overexpress a mutated AR and represent cells that have adapted the AR
pathway to be able to grow and survive in patients treated with hormone therapy [35,
36]. It has been reported that ﬂutamide can behave as an agonist on AR phos-
phorylation (i.e., activation), resulting in increased PSA expression in LNCaP cells
[18]. This feature is closely related to our results with the same cell line cultured with
CSS (to deprive the cells of androgens, other steroids and, in all likelihood, some
growth factors) since ﬂutamide augmented the expression of PKCb1 isoenzyme in
contrast as CSS did. However, when LNCaP cells were cultured in a medium with
full serum, ﬂutamide showed diverse eﬀects on the expression of PKC isoenzymes,
which may be due to the diﬃculty in blocking all available androgens. This point is
relevant since androgen ablation in patients with prostate cancer does not result in
total abolition of androgen levels [9,10].
Our observation that ﬂutamide stimulates the expression of PKC isoenzymes in
almost all the conditions tested (either in the presence or absence of androgens) in
PC3 cells was quite surprising. In addition, we did not ﬁnd any expression of AR by
RT-PCR. The mechanism of action of ﬂutamide underlying the regulation of PKC
expression in PC3 cells remains unknown but is of interest since many subpopula-
tions of cells have lost AR expression altogether in the late-stage of androgen-
independent prostate cancer [36]. In this context, because biological responses
require the integration of diverse signals, a full understanding of the consequences of
ﬂutamide eﬀects on the expression and activity of PKC isoenzymes may be valuable.
In summary, the present report demonstrates that the antiandrogen ﬂutamide
up-regulates the expression of various PKC isoenzymes in androgen-deprived
LNCaP cells. Whether such an eﬀect is exerted via the mutated AR molecule of these
cells and/or other target molecules remains unclear. These eﬀects are also detected in
PC3 cells, which lack AR expression, so that they must be conceivably reached, at
least in this case, through an androgen-independent mechanism. The results rein-
force and extend previous observations on the changing agonistic or antagonistic
activity of drugs used in the treatment of prostate cancer, depending on the extent of
the mutation and the phosphorylation/dephosphorylation status of the AR [12–18],
and describe for the ﬁrst time an eﬀect of ﬂutamide that is independent of the AR.
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